Adaptive Biotechnologies (ADPT) Price to Sales (2019 - 2026)

Adaptive Biotechnologies has disclosed Price to Sales across 8 years of filings, most recently posting 47.68 for Q2 2026.

• In Q2 2026, Price to Sales rose 58.3% year-over-year to 47.68; the TTM figure through Jun 2026 stood at 11.07 (up 28.14% YoY), while the FY2025 annual figure was 9.02, up 82.29% from the prior year.
• Price to Sales came in at 47.68 for Q2 2026 at Adaptive Biotechnologies, up from 31.28 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 51.1 in Q1 2022 to a low of 11.3 in Q1 2024.
• Average Price to Sales over 5 years is 25.39, with a median of 21.4 recorded in 2022.
• Year-over-year, Price to Sales plunged 82.48% in 2022 and surged 143.71% in 2025.
• Over 5 years, Price to Sales stood at 19.81 in 2022, then dropped by 21.61% to 15.53 in 2023, then increased by 20.12% to 18.65 in 2024, then jumped by 86.8% to 34.84 in 2025, then soared by 36.86% to 47.68 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 47.68 in Q2 2026, 31.28 in Q1 2026, and 34.84 in Q4 2025.